Synthetic Biologics Inc (NYSEMKT:SYN) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a report issued on Saturday.

A number of other equities research analysts also recently weighed in on SYN. Zacks Investment Research downgraded shares of Synthetic Biologics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. ValuEngine upgraded shares of Synthetic Biologics from a “strong sell” rating to a “sell” rating in a research report on Friday, August 18th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $3.92.

Shares of Synthetic Biologics (NYSEMKT:SYN) opened at $0.79 on Friday. Synthetic Biologics has a 1 year low of $0.41 and a 1 year high of $1.60.

Synthetic Biologics (NYSEMKT:SYN) last issued its quarterly earnings data on Wednesday, November 1st. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by ($0.10).

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/11/04/synthetic-biologics-inc-syn-downgraded-to-sell-at-bidaskclub.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Susquehanna International Group LLP raised its position in shares of Synthetic Biologics by 76.4% in the second quarter. Susquehanna International Group LLP now owns 189,342 shares of the company’s stock valued at $107,000 after buying an additional 82,030 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Synthetic Biologics by 8,102.7% in the second quarter. Goldman Sachs Group Inc. now owns 1,129,108 shares of the company’s stock valued at $639,000 after buying an additional 1,115,343 shares in the last quarter. LMR Partners LLP acquired a new stake in shares of Synthetic Biologics in the second quarter valued at approximately $194,000. Creative Planning raised its position in shares of Synthetic Biologics by 65.4% in the second quarter. Creative Planning now owns 177,000 shares of the company’s stock valued at $100,000 after buying an additional 70,000 shares in the last quarter. Finally, UBS Group AG raised its position in shares of Synthetic Biologics by 10.3% in the first quarter. UBS Group AG now owns 214,357 shares of the company’s stock valued at $135,000 after buying an additional 20,038 shares in the last quarter.

About Synthetic Biologics

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.